ADRIM has a wide spectrum of antineoplastic activity. It has been used successfully to produce regression in many neoplastic conditions like acute lymphoblastic and myeloblastic leukemias, malignant lymphomas of both Hodgkin’s and Non Hodgkin’s type, carcinoma of the breast, lung, bladder, gastric, thyroid as well as ovarian carcinoma, bone and soft tissue sarcomas, neuroblastoma and Wilm’s tumour. The drug has also demonstrated activity in carcinoma of endometrium, testes, prostate and cervix.